Taro Pharma (69% US subsidiary; ~20%/60% of Sun's sales/profit) delivered disappointing Q2 results with 15%/26% yoy decline in sales/profits to US$ 212mn (12%belowestimate)/US$106mn(15%below).Withthisdismalperformance,wecut...